Study on the therapeutic effect of anti SARS-CoV-2 drugs on COVID-19 patients in Chinese medical and health institutions

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300074507

Enrollment

Unknown

Registered

2023-08-08

Start date

2023-06-05

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Group without anti SARS-CoV-2 drugs:None

Group with anti SARS-CoV-2 drugs:None

Eligibility

Sex/Gender

All

Age

18 Years to 120 Years

Inclusion criteria

Inclusion criteria: 1. Age = 18 years old; 2. Male or female; 3. SARS-CoV-2 antigen or Nucleic acid test test is positive; 4. Diagnosed as light or medium according to the ‘Scheme for Diagnosis and Treatment of novel coronavirus Infection(The 10th Trial Edition)’

Exclusion criteria

Exclusion criteria: 1.Patient does not agree to sign informed consent; 2.Patient took anti SARS-CoV-2 drugs within 7 days

Design outcomes

Primary

Measure	Time frame
Progressive Severity Incidence;	—

Secondary

Measure	Time frame
Duration of SARS-CoV-2 virus turning negative;Time of disappearance of SARS-CoV-2 symptoms;Incidence rate of Serious adverse event;Proportion of anti COVID-19 drugs used;EQ-5D-5L rating;COVID-19 related outpatient service costs;Number of outpatient visits related to COVID-19;COVID-19 related outpatient fees;Length of COVID-19 related hospitalization;Non-medical costs;	—

Countries

China

Contacts

Public ContactRongmeng Jiang

Beijing Ditan Hospital, Capital Medical University

13911900791@163.com+86 10 8432 2071

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026